<DOC>
	<DOCNO>NCT00485810</DOCNO>
	<brief_summary>The purpose study examine clinical therapeutic dose Japanese agitated patient schizophrenia .</brief_summary>
	<brief_title>Examining Rapid Acting Intra-Muscular Olanzapine Japanese Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Male female patient least 20 year age less 65 year old Patients must inpatient study Patients must diagnosis schizophrenia per DSMIV , determine investigator Patients must consider investigator clinically agitate clinically appropriate candidate treatment intramuscular ( IM ) medication Patients must minimum total score great equal 14 5 item PANSSEC least one individual item score great equal 4 use 17 score system , prior first IM injection study drug Serious , unstable illness death anticipate within 1 year intensive care unit hospitalization disease anticipate within 6 month . This include hepatic ( specifically degree jaundice ) , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease Known history seizure ; however , patient whose etiology identifiable resolve may enrol Known history diabetes mellitus , complication diabetes mellitus , potential diabetes mellitus defined patient single blood glucose measurement base site test ; patient value great equal 140 mg/dL ( nonfasting ) great equal 110 mg/dL ( fast ) must exclude study History allergic reaction intolerance olanzapine Have receive treatment psychostimulants reserpine within 1 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>